Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
78.6M
-
Shares change
-
+3.15M
-
Total reported value, excl. options
-
$444M
-
Value change
-
+$18.8M
-
Put/Call ratio
-
2.34
-
Number of buys
-
73
-
Number of sells
-
-77
-
Price
-
$5.64
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q4 2024
194 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.6M shares
of 89.6M outstanding shares and own 87.77% of the company stock.
Largest 10 shareholders include Alphabet Inc. (12.3M shares), BlackRock, Inc. (7.53M shares), BVF INC/IL (6.9M shares), VANGUARD GROUP INC (4.01M shares), Casdin Capital, LLC (4M shares), MILLENNIUM MANAGEMENT LLC (3.92M shares), Schonfeld Strategic Advisors LLC (3.79M shares), STATE STREET CORP (3.24M shares), Novo Holdings A/S (2.4M shares), and T. Rowe Price Investment Management, Inc. (2.35M shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.